N-butyl-β-carboline-3-carboxylate (β-CCB) systemic administration promotes remyelination in the cuprizone demyelinating model in mice.

Autor: Vélez-Uriza, Fidel¹ (AUTHOR), Ordaz, Rainald Pablo¹ (AUTHOR), Garay, Edith¹ (AUTHOR), Cisneros-Mejorado, Abraham J.¹ (AUTHOR) acisneros@conahcyt.mx, Arellano, Rogelio O.¹ (AUTHOR) arellano.ostoa@comunidad.unam.mx

Publikováno v: Scientific Reports. 6/17/2024, Vol. 14 Issue 1, p1-17. 17p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

GABA A Receptors Expressed in Oligodendrocytes Cultured from the Neonatal Rat Contain α 3 and γ 1 Subunits and Present Differential Functional and Pharmacological Properties.

Autor: Ordaz RP; Instituto de Neurobiología, Laboratorio de Neurofisiología Celular, Universidad Nacional Autónoma de México, Juriquilla, Querétaro, México (R.P.O., E.G., L.R.-M., A.C.-M., R.O.A.); Mitchell Center for Neurodegenerative Diseases, Department of Neurology, School of Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas (A.L.); and Achucarro Basque Center for Neuroscience, CIBERNED and Departamento de Neurociencias, Universidad del País Vasco (UPV/EHU), Leioa, Spain (A.P.-S., M.V.S.-G., C.M.)., Garay E; Instituto de Neurobiología, Laboratorio de Neurofisiología Celular, Universidad Nacional Autónoma de México, Juriquilla, Querétaro, México (R.P.O., E.G., L.R.-M., A.C.-M., R.O.A.); Mitchell Center for Neurodegenerative Diseases, Department of Neurology, School of Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas (A.L.); and Achucarro Basque Center for Neuroscience, CIBERNED and Departamento de Neurociencias, Universidad del País Vasco (UPV/EHU), Leioa, Spain (A.P.-S., M.V.S.-G., C.M.)., Limon A; Instituto de Neurobiología, Laboratorio de Neurofisiología Celular, Universidad Nacional Autónoma de México, Juriquilla, Querétaro, México (R.P.O., E.G., L.R.-M., A.C.-M., R.O.A.); Mitchell Center for Neurodegenerative Diseases, Department of Neurology, School of Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas (A.L.); and Achucarro Basque Center for Neuroscience, CIBERNED and Departamento de Neurociencias, Universidad del País Vasco (UPV/EHU), Leioa, Spain (A.P.-S., M.V.S.-G., C.M.)., Pérez-Samartín A; Instituto de Neurobiología, Laboratorio de Neurofisiología Celular, Universidad Nacional Autónoma de México, Juriquilla, Querétaro, México (R.P.O., E.G., L.R.-M., A.C.-M., R.O.A.); Mitchell Center for Neurodegenerative Diseases, Department of Neurology, School of Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas (A.L.); and Achucarro Basque Center for Neuroscience, CIBERNED and Departamento de Neurociencias, Universidad del País Vasco (UPV/EHU), Leioa, Spain (A.P.-S., M.V.S.-G., C.M.)., Sánchez-Gómez MV; Instituto de Neurobiología, Laboratorio de Neurofisiología Celular, Universidad Nacional Autónoma de México, Juriquilla, Querétaro, México (R.P.O., E.G., L.R.-M., A.C.-M., R.O.A.); Mitchell Center for Neurodegenerative Diseases, Department of Neurology, School of Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas (A.L.); and Achucarro Basque Center for Neuroscience, CIBERNED and Departamento de Neurociencias, Universidad del País Vasco (UPV/EHU), Leioa, Spain (A.P.-S., M.V.S.-G., C.M.)., Robles-Martínez L; Instituto de Neurobiología, Laboratorio de Neurofisiología Celular, Universidad Nacional Autónoma de México, Juriquilla, Querétaro, México (R.P.O., E.G., L.R.-M., A.C.-M., R.O.A.); Mitchell Center for Neurodegenerative Diseases, Department of Neurology, School of Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas (A.L.); and Achucarro Basque Center for Neuroscience, CIBERNED and Departamento de Neurociencias, Universidad del País Vasco (UPV/EHU), Leioa, Spain (A.P.-S., M.V.S.-G., C.M.)., Cisneros-Mejorado A; Instituto de Neurobiología, Laboratorio de Neurofisiología Celular, Universidad Nacional Autónoma de México, Juriquilla, Querétaro, México (R.P.O., E.G., L.R.-M., A.C.-M., R.O.A.); Mitchell Center for Neurodegenerative Diseases, Department of Neurology, School of Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas (A.L.); and Achucarro Basque Center for Neuroscience, CIBERNED and Departamento de Neurociencias, Universidad del País Vasco (UPV/EHU), Leioa, Spain (A.P.-S., M.V.S.-G., C.M.)., Matute C; Instituto de Neurobiología, Laboratorio de Neurofisiología Celular, Universidad Nacional Autónoma de México, Juriquilla, Querétaro, México (R.P.O., E.G., L.R.-M., A.C.-M., R.O.A.); Mitchell Center for Neurodegenerative Diseases, Department of Neurology, School of Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas (A.L.); and Achucarro Basque Center for Neuroscience, CIBERNED and Departamento de Neurociencias, Universidad del País Vasco (UPV/EHU), Leioa, Spain (A.P.-S., M.V.S.-G., C.M.) carlos.matute@ehu.eus., Arellano RO; Instituto de Neurobiología, Laboratorio de Neurofisiología Celular, Universidad Nacional Autónoma de México, Juriquilla, Querétaro, México (R.P.O., E.G., L.R.-M., A.C.-M., R.O.A.); Mitchell Center for Neurodegenerative Diseases, Department of Neurology, School of Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas (A.L.); and Achucarro Basque Center for Neuroscience, CIBERNED and Departamento de Neurociencias, Universidad del País Vasco (UPV/EHU), Leioa, Spain (A.P.-S., M.V.S.-G., C.M.) arellano.ostoa@comunidad.unam.mx.

Publikováno v: Molecular pharmacology [Mol Pharmacol] 2021 Feb; Vol. 99 (2), pp. 133-146. Date of Electronic Publication: 2020 Dec 07.